Kisqali uses?

Kisqali (ribociclib) is a CDK4/6 inhibitor used for HR-positive, HER2-negative advanced or metastatic breast cancer. It’s given in combination with hormonal therapy. Typical approved uses include:

- In postmenopausal women: ribociclib plus letrozole as initial endocrine therapy for HR+/HER2− advanced or metastatic breast cancer.
- In patients who have progressed after prior endocrine therapy: ribociclib plus fulvestrant.
- In premenopausal or perimenopausal women (in combination with tamoxifen and goserelin) for HR+/HER2− advanced or metastatic breast cancer (based on specific regional approvals).

Notes:
- Not approved for HER2-positive or triple-negative breast cancer.
- Exact indications can vary by country; always check the local labeling and consult a clinician for individual treatment decisions.